{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:16:27Z","timestamp":1791411387866,"version":"4.3.3"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ctrv.2017.05.008","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T06:02:07Z","timestamp":1497420127000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Mantle cell lymphoma \u2013 Current standards of care and future directions"],"prefix":"10.1016","volume":"58","author":[{"given":"Peter","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.05.008_b0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0015","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.05.008_b0020","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0025","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V126.23.2699.2699","article-title":"Outcome of observation as initial strategy in patients with mantle cell lymphoma","volume":"126","author":"Abrisqueta","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0030","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.05.008_b0035","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0040","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/modpathol.2015.99","article-title":"Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype","volume":"28","author":"Ribera-Cortada","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0045","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0050","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD anderson cancer center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0060","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0065","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0070","doi-asserted-by":"crossref","unstructured":"Chen R-W, Li H, Bernstein S-H, Kahwash S, Rimsza L-M, Forman S-J, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 2016 Dec 19. [Epub ahead of print] doi: http:\/\/dx.doi.org\/10.1111\/bjh.14480.","DOI":"10.1111\/bjh.14480"},{"key":"10.1016\/j.ctrv.2017.05.008_b0075","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0080","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefr\u00e8re","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2017.05.008_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.05.008_b0095","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.05.008_b0100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.05.008_b0105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3109\/10428194.2013.825906","article-title":"High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial","volume":"55","author":"Laurell","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.145.145","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: Final results of the randomized phase 3 LyMa trial of the lysa\/goelams group","volume":"128","author":"Le Gouill","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.008_b0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2017.05.008_b0120","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.008_b0125","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0130","article-title":"the Nordic Lymphoma Group phase I+II trial NLG-MCL4","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0135","doi-asserted-by":"crossref","unstructured":"Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, et al. Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. Haematologica; 2017. pii: haematol.2016.154211. [Epub ahead of print] doi: http:\/\/dx.doi.org\/10.3324\/haematol.2016.154211.","DOI":"10.3324\/haematol.2016.154211"},{"issue":"3","key":"10.1016\/j.ctrv.2017.05.008_b0140","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ctrv.2017.05.008_b0145","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2017.05.008_b0150","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0155","article-title":"Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: A phase II clinical trial blood","volume":"128","author":"Wang","year":"2016"},{"key":"10.1016\/j.ctrv.2017.05.008_b0160","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"s1","key":"10.1016\/j.ctrv.2017.05.008_b0165","first-page":"3","article-title":"High dose sequential chemotherapy with rituximab and ASCT as first line therapy in adult MCL patients: clinical and molecular response of the MCL0208 trial, a FIL study","volume":"100","author":"Cortelazzo","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ctrv.2017.05.008_b0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"European mantle cell lymphoma network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0175","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.V114.22.880.880","article-title":"Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma","volume":"114","author":"Hoster","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0180","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.05.008_b0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0190","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V126.23.337.337","article-title":"Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403","volume":"126","author":"Kaplan","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V126.23.339.339","article-title":"Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study","volume":"126","author":"Doorduijn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0200","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3109\/10428194.2014.940584","article-title":"Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network","volume":"56","author":"Dreyling","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2017.05.008_b0205","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.05.008_b0210","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ctrv.2017.05.008_b0215","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00277-014-2077-1","article-title":"Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience","volume":"93","author":"Garc\u00eda-Noblejas","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.008_b0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2017.05.008_b0225","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2017.05.008_b0230","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2017.05.008_b0235","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.ctrv.2017.05.008_b0240","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.05.008_b0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2017.05.008_b0250","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2017.05.008_b0255","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0260","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0265","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0270","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","article-title":"Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma","volume":"29","author":"Hess","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0275","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V128.22.2977.2977","article-title":"Temsirolimus in combination with Bendamustine and Rituximab (BeRT) for the treatment of relapsed mantle cell and follicular lymphoma: final phase I\/II results","volume":"128","author":"Hess","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0280","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.008_b0285","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0290","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1182\/blood.V126.23.3980.3980","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory mantle cell lymphoma; results of a phase II trial","volume":"126","author":"Kolibaba","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0295","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V128.22.148.148","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: First results from the nordic lymphoma group MCL6 (PHILEMON) phase II trial","volume":"128","author":"Jerkeman","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0300","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood.V128.22.150.150","article-title":"A phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0305","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.V128.22.641.641","article-title":"TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL or MCL: Preliminary results of a multicenter phase I\/Ib study","volume":"128","author":"Davids","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0310","doi-asserted-by":"crossref","unstructured":"Tam C-S-L, Warwick Roberts A, Anderson M-A, Dawson S-J, Hicks R-J, Pott C, et al. The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed\/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. J Clin Oncol 34, 2016 (suppl; abstr 7548) [ASCO meeting 2016, abstract # 7548].","DOI":"10.1200\/JCO.2016.34.15_suppl.7548"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0315","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.V128.22.2958.2958","article-title":"Initial report of a multi-institution phase I\/Ib study of ibrutinib with venetoclax in relapsed or refractory mantle cell lymphoma","volume":"128","author":"Portell","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2017.05.008_b0320","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davis","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0325","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0330","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"Is safe, tolerable, and highly active in patients with relapsed\/ refractory B-cell malignancies: Initial report of a phase 1 first-in-human trial","volume":"126","author":"Tam","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2017.05.008_b0335","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0340","doi-asserted-by":"crossref","unstructured":"Hoster E1, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558\u201365. Epub 2007 Oct 25. doi: http:\/\/dx.doi.org\/10.1182\/blood-2007-06-095331.","DOI":"10.1182\/blood-2007-06-095331"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.008_b0345","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2017.05.008_b0350","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0355","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.V126.23.336.336","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0360","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V128.22.1095.1095","article-title":"Targeted sequencing of diagnostic samples correlated to clinical outcome: Data from the nordic mantle cell lymphoma (MCL2 and MCL3) studies with long-term follow-up","volume":"128","author":"Eskelund","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2017.05.008_b0365","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0370","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2017.05.008_b0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2017.05.008_b0380","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.008_b0385","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood.V126.23.338.338","volume":"126","author":"Callanan","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2017.05.008_b0390","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ctrv.2017.05.008_b0395","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.008_b0400","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood.V128.22.146.146","volume":"128","author":"Kolstad","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.05.008_b0405","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ctrv.2017.05.008_b0410","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: A comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721730097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721730097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T04:32:06Z","timestamp":1602304326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721730097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":82,"alternative-id":["S030573721730097X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mantle cell lymphoma \u2013 Current standards of care and future directions","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}